Whats New at V3 - Akcea Therapeutics

August 16, 2019

Here's a quick look at

what we've been up to...

Akcea Therapeutics


Akcea, are on a mission to transform the treatment of unaddressed or under-addressed serious and rare diseases with leading-edge, RNA-targeted medicines. 


Familial chylomicronemia syndrome (FCS) is a serious and rare lipid disorder characterized by the build-up of chylomicrons (chylomicronemia), a large lipoprotein particle that transport dietary fat and cholesterol in the body. Because chylomicrons are rich in triglycerides, people with FCS have extremely high levels of triglycerides, often reaching 10 to 20 times the normal level. People with FCS cannot break down chylomicrons, so their blood can appear milky in color (lipemic). There are approximately 3,000 to 5,000 patients with FCS worldwide. - Click here to go to their website


The Pop up banner was printed here at V3


Share on Facebook
Share on Twitter
Please reload

Featured Posts

It’s finally here, A-Level Results Day!

August 13, 2020

Please reload

Recent Posts

April 24, 2020

March 19, 2020

March 17, 2020

February 28, 2020

Please reload

Please reload

Search By Tags

I'm busy working on my blog posts. Watch this space!

Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square
  • Grey Instagram Icon
  • Grey Facebook Icon
  • Grey Twitter Icon

V3 is ISO 14001 Certificate No. EM2000986 registered

V3 is a member of the UK Design & Print Network

Website created by v3 design+print weybridge © 2017 by the v3 group

Join our mailing list & never miss an update